Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-18

Multifunctional theranostic nanoparticles using pH-responsive DNA-nanoparticle conjugate for effective cancer therapy

Objectif

Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. Although conventional cancer chemotherapy can provide profound benefits, seriously adverse side-effects still cannot be avoided, due to lack of specific targeting nature of current treatments. Nanomedicine can reduce such side-effects by exploiting characteristic properties of tumors for targeted delivery and therapy. Despite extensive research, most nanomedicines developed so far have relied on passive targeting using a single therapeutic modality, which are inefficient for treatment of challenging conditions such as multi-drug resistance.

Recently we developed a pH-responsive-DNA-GNP conjugate based nanocarrier that numerous features required for an ideal drug nanocarrier, e.g. uniform small nanoscale size, resisting non-specific adsorption, non-toxic, biocompatible, water-soluble, stable, and having high drug loading and controlled release capacities. It can offer efficient and pH-triggered drug release suitable for effective cancer chemotherapy at the cellular level using doxorubicin, a widely used chemotherapy drug.

Herein we will extend it into a more effective, multifunctional nanomedicine that can offer simultaneous biomodal chemotherapies with hyperthermia and MRI imaging capacities. First, we will prepare, characterize, and evaluate their drug loading & release profiles in buffer; then we will study and quantify their cell- & cell-specific- uptake and drug delivery efficiency, and then evaluate their toxicity, cytotoxicity & cell-specific cytotoxicity with cancer cells (incoming phase), and finally evaluate their synergistic therapeutic efficacy at cellular and preclinical level (re-integration phase). This project will greatly benefit both the fundamental research in nanomedicine and the healthcare/pharmaceutical indurstries in Europe.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Appel à propositions

FP7-PEOPLE-2012-IIF
Voir d’autres projets de cet appel

Régime de financement

MC-IIF - International Incoming Fellowships (IIF)

Coordinateur

UNIVERSITY OF LEEDS
Contribution de l’UE
€ 309 235,20
Adresse
WOODHOUSE LANE
LS2 9JT Leeds
Royaume-Uni
Région
Yorkshire and the Humber West Yorkshire Leeds
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée